# ATHN 2: Factor Switching Study

> **NCT02546622** · — · COMPLETED · sponsor: **American Thrombosis and Hemostasis Network** · enrollment: 310 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **BIOLOGICAL:** Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013
- **BIOLOGICAL:** Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013

## Key facts

- **NCT ID:** NCT02546622
- **Lead sponsor:** American Thrombosis and Hemostasis Network
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2021-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546622, "ATHN 2: Factor Switching Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02546622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*